MINGSIGHT PHARMACEUTICALS

Mingsight, an ophthalmic medical drug developer, has initiated a clinical trial of the original innovative drug MS-553 in patients with diabetic retinopathy. This study is the world's first clinical trial of MS-553 in this indication. In the field of CLL treatment, MS-533 can be used alone or in combination with ibrutinib, BCL-2, etc., initially showing outstanding clinical value and market potential in the treatment of patients with C481S and PLCG2 mutations; in the field of DME treatment, MS-533 can be taken orally to achieve enrichment in the retina of the fundus, avoiding the need for vitreous injection of drugs such as ranibizumab, and clinical data such as BCVA/CRT of patients also initially show the efficacy of the product.